Exchange: NYSE·Updated 07:30 PM EDT

QGEN News

News
all
press releases
QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will hold an Extraordinary General Meeting of Shareholders on November 6, 2026, at 2:00 p.m. CET. Shareholders will be asked to vote on the appointment of Jonathan M. Pratt to the QIAGEN Managing Board after he joined...
Business Wire
More News
Qiagen (QGEN) Shares Cross Below 200 DMA
In trading on Tuesday, shares of Qiagen NV (Symbol: QGEN) crossed below their 200 day moving average of $42.73, changing hands as low as $42.22 per share. Qiagen NV shares are currently trading off about 2.2% on the day. The chart below shows the one year performance of QGEN s...
Nasdaq News: Markets
Qiagen (QGEN) Up 5.1% Since Last Earnings Report: Can It Continue?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit
10x Genomics won a $4.8 million patent infringement lawsuit against Qiagen subsidiary Parse Biosciences, prompting plans for an injunction.read more...
Benzinga
TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences
10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks added damages and a U.S. injunction.
Zacks
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences PR Newswire PLEASANTON, Calif., Aug. 28, 2026 Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity...
PR Newswire
QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide...
Business Wire
Qiagen Appoints Jonathan Pratt To Succeed Thierry Bernard As CEO
(RTTNews) - QIAGEN N.V. (QGEN) announced Monday that Jonathan Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare...
Nasdaq News: Markets
QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and...
Business Wire
Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building?
BIO's 19.1% monthly rally is backed by digital PCR gains and steadier diagnostics, but weak Life Science demand and a rich valuation loom.
Zacks

Advertisement|Remove ads.